 RespireRx Pharmaceuticals OTC:RSPI Inc revealed that the company and the Board of Trustees of University of Illinois UIL, have agreed to a second amendment to their Exclusive License Agreement. In a statement, RespireRx interim CEO Arnold Lippa said: As we have previously announced, the company has formed ResolutionRx, an unlisted public Australian company, for the purpose of developing pharmaceutical cannabinoids, with an initial focus on our proprietary formulated dronabinol. 